Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers-Reference-Cited by-同舟云学术

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers

Published:2007-01 Issue:3 Volume:25 Page:510-518
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Goepfert Paul A.,Tomaras Georgia D.,Horton Helen,Montefiori David,Ferrari Guido,Deers Mark,Voss Gerald,Koutsoukos Marguerite,Pedneault Louise,Vandepapeliere Pierre,McElrath M. Juliana,Spearman Paul,Fuchs Jonathan D.,Koblin Beryl A.,Blattner William A.,Frey Sharon,Baden Lindsey R.,Harro Clayton,Evans Thomas

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference53 articles.

1. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group;Graham;Ann Intern Med,1996

2. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group;Clements-Mann;J Infect Dis,1998

3. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network;Dolin;Ann Intern Med,1991

4. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans;Evans;Vaccine,2001

5. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320;McCormack;Vaccine,2000

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of a DNA vaccine with subtype C gp120 protein adjuvanted with MF59® or AS01B: a phase 1/2a HIV-1 vaccine trial;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-05-03

2. Monophosphoryl Lipid A-Rhamnose Conjugates as a New Class of Vaccine Adjuvants;Journal of Medicinal Chemistry;2024-04-18

3. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses;Science Translational Medicine;2023-05-24

4. Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review);International Journal of Oncology;2023-05-05

5. Adjuvant physiochemistry and advanced nanotechnology for vaccine development;Chemical Society Reviews;2023